QS Research · Michael Burry's Scion Capital analyst template · 2006
KIMBERLY CLARK CORP (KMB)
As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data
Report price $108.15 (close 2026-11-17); latest close $106.38 (2026-11-20), -1.6% since the report; figures re-marked at the latest close
Conclusion: PASS
Conviction low · base case none · downside -31% · upside +27%
At $108.15, the market prices only +1.4% annual revenue growth for ten years at an 11.7% FCF margin, against -2.1% latest fiscal-year growth. That is a low bar, but the shares are not cheap on clean earnings: adjusted P/E is 38.0x while GAAP P/E is 20.1x, flattered by $1.55B of discontinued operations, 47% of net income. The Kenvue deal also adds shares and debt before the first combined print, so the risk and reward are not decisively skewed. PASS is the call: there is no base case, because the peers' P/E is GAAP and the company's GAAP P/E (20.1x) is more than 5% from the adjusted P/E the downside is on (38x), so a base at the peer multiple would sit on other earnings than the downside and upside. Downside is -31.8% to $73.71, on -10.0% earnings at a compressed P/E of 29.0x (today 38.0x). Upside is +25.0% to $135.19, on +25% earnings at today's P/E of 38x.
Key numbers
- Share price: $106.38
- Market cap: $65.28B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $16.57B
- EV / EBITDA (TTM): 22.3x
- P/E (TTM): 19.8x
- FCF yield: 2.9%
- Price / book: 22.27x
- Earnings-quality flags (TTM): Discontinued operations $1.55B (47% of net income)
- P/E, adjusted (TTM): 37.4x
- EV / FCF (TTM): 35.9x
- Revenue growth (latest fiscal year): -2.1%
- ROIC (TTM): 22.2%
- WACC: 5.5%
- Economic profit spread: +16.8 pts
The 15 boxes
- ✓ 1. Long-form business notes
Kimberly-Clark makes and sells daily-need paper and nonwoven products under No. 1/No. 2 brands (Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, WypAll) in more than 175 countries, sold direct to supermarkets, mass merchandisers, drugstores, clubs and e-commerce, with Walmart alone about 16% of 2025 net sales from continuing operations. The business has been reshaped between the two annual reports: the FY2020 filing ran three product segments (Personal Care, Consumer Tissue, K-C Professional), while the FY2025 filing runs two geographic segments (North America, International Personal Care) after the International Family Care and Professional business was put into a Suzano joint venture and reported as discontinued operations, with a pending all-stock-and-cash acquisition of Kenvue signed November 2, 2025. Scale has shrunk on the top line: revenue was $19.14B in FY2020 and $16.45B in FY2025, with $16.57B on a TTM basis to September 30, 2026, and operating income $2.35B in FY2025 versus $3.24B in FY2020. Cash generation remains the core: operating cash flow $2.78B in FY2025 and $3.38B TTM against capex $1.14B and $1.44B respectively, while buybacks fell to $141.0M in FY2025 and $1.0M TTM from $1.00B in FY2024.
- ✓ 2. Competitive advantage
The sources do not establish a durable competitive advantage: K-C competes in highly competitive domestic and international markets against branded and private-label products, and large retailers and e-tailers have significant bargaining power. Margin and cash-flow history shows scale and positive cash generation, but FY2025 and TTM to 2026-09-30 gross profit and operating income remain below FY2022 levels, and TTM net income is above pre-tax income so it is not an operating measure. Brand reputation is called critical, but the same filing stresses private-label, input-cost and pricing pass-through risks; no market-share or pricing-power data is given.
- ✓ 3. 10-Q takeaways
Q3 2026 sales fell to $4,134M from $4,150M, and operating profit fell to $516M from $621M as marketing, research and general expenses rose; nine-month sales and operating profit were up. Reported Q3 net income of $1,793M is not an operating result: $1,395M came from discontinued operations tied to the IFP sale gain. Cash rose to $1,874M, inventories to $1,579M, no buybacks in the nine months to Sep 2026, and the Oct 15 release kept FY2026 outlook with organic sales about 100 bps below category growth and adjusted operating profit mid-single-digit constant-currency growth. The supplemental risk factors focus on Kenvue integration, higher debt and dividend cash needs, and product-safety exposure.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.